ITI Pharma and Healthcare Fund Direct Growth

ITI Pharma and Healthcare Fund Direct Growth

Equity
Sectoral
Very High Risk
+20.02%
3Y annualised
-0.95% 1D
1M
6M
1Y
3Y
All
NAV: 19 Jan '26
₹16.55
Min. SIP amount
₹500
Fund size
₹223.80 Cr
Expense ratio
0.47%

Return calculator

Monthly SIP
One time
Monthly investment
₹5,000
Over the pastTotal investmentWould've becomeHistoric returnsReturns
1 year₹60,000₹58,665
-2.23%
3 years₹1,80,000₹2,15,297
+19.61%

Holdings (41)

NameSectorInstrumentsAssets
Sun Pharmaceutical Industries Ltd.HealthcareEquity10.91%
Divi's Laboratories Ltd.HealthcareEquity8.90%
Apollo Hospitals Enterprise Ltd.HealthcareEquity5.91%
Max Healthcare Institute Ltd.HealthcareEquity5.64%
Torrent Pharmaceuticals Ltd.HealthcareEquity4.55%
Aurobindo Pharma Ltd.HealthcareEquity4.00%
Fortis Healthcare Ltd.HealthcareEquity3.58%
Cohance Lifesciences Ltd.HealthcareEquity3.45%
Lupin Ltd.HealthcareEquity3.40%
Alkem Laboratories Ltd.HealthcareEquity3.06%
Aster DM Healthcare Ltd.HealthcareEquity2.95%
Neuland Laboratories Ltd.HealthcareEquity2.79%
Wockhardt Ltd.HealthcareEquity2.51%
Abbott India Ltd.HealthcareEquity2.40%
Laurus Labs Ltd.HealthcareEquity2.05%
Cipla Ltd.HealthcareEquity1.94%
Glenmark Pharmaceuticals Ltd.HealthcareEquity1.94%
Dr. Reddy's Laboratories Ltd.HealthcareEquity1.79%
Mankind Pharma Ltd.HealthcareEquity1.72%
Sai Life Sciences Ltd.HealthcareEquity1.61%
FDC Ltd.HealthcareEquity1.44%
Ipca Laboratories Ltd.HealthcareEquity1.43%
Healthcare Global Enterprises Ltd.HealthcareEquity1.40%
Sumitomo Chemical India Ltd.ChemicalsEquity1.36%
SBI Life Insurance Company Ltd.InsuranceEquity1.35%
Biocon Ltd.HealthcareEquity1.33%
Orchid Pharma Ltd.HealthcareEquity1.23%
Piramal Pharma Ltd.HealthcareEquity1.21%
Onesource Specialty Pharma Ltd.HealthcareEquity1.21%
Rainbow Children's Medicare Ltd.HealthcareEquity1.19%
Park Medi World Ltd.HealthcareEquity1.17%
Linde India Ltd.ChemicalsEquity1.09%
Standard Glass Lining Technology Ltd.Capital GoodsEquity1.04%
Glaxosmithkline Pharmaceuticals Ltd.HealthcareEquity1.02%
Poly Medicure Ltd.HealthcareEquity0.95%
Caplin Point Laboratories Ltd.HealthcareEquity0.86%
Supriya Lifescience Ltd.HealthcareEquity0.85%
Astrazeneca Pharma India Ltd.HealthcareEquity0.76%
Shilpa Medicare Ltd.HealthcareEquity0.71%
Zydus Lifesciences Ltd.HealthcareEquity0.69%
Syngene International Ltd.HealthcareEquity0.50%
See All

Minimum investments

Min. for 1st investment
₹5,000
Min. for 2nd investment
₹1,000
Min. for SIP
₹500

Returns and rankings

Annualised returns
Absolute returns
Name6M1Y3YAll
Fund returns-7.9%-4.2%+20.0%+13.0%
Category average (Equity Sectoral)+0.2%-2.1%+22.1%--
Rank (Equity Sectoral)--2111--

Exit load, stamp duty and tax

Exit load

Exit load of 0.50%, if redeemed within 3 months.

Stamp duty on investment: 0.005% (from July 1st, 2020)

from July 1st 2020

Tax implication

If you redeem within one year, returns are taxed at 20%. If you redeem after one year, returns exceeding Rs 1.25 lakh in a financial year are taxed at 12.5%.
Check past data

Fund management

DS
Dhimant Shah
Dec 2022 - Present
View details

Education
Mr. Shah is a B.Com (H) and Chartered Accountant.
Experience
Prior to joining ITI Mutual Fund, he has worked with Principal Mutual Fund, HSBC AMC, Reliance Mutual Fund, ASK Raymond James Securities Pvt. Ltd. and IL&FS AMC. Senior Analyst from April 1997 to August 2003.

RB
Rajesh Bhatia
Jun 2024 - Present
View details

Education
Mr. Bhatia has done B.Com, ACMA and CFA
Experience
Prior to joining ITI Mutual Fund, he was associated with The Investment Trust Of India Ltd, Simto Investment Company Ltd, ProAlpha Systematic Capital, Heritage India Advisors Ltd and Reliance Capital Asset Management Ltd

About ITI Pharma and Healthcare Fund Direct Growth

ITI Pharma and Healthcare Fund Direct Growth is a Equity Mutual Fund Scheme launched by ITI Mutual Fund. This scheme was made available to investors on 14 May 2018. Dhimant Shah is the Current Fund Manager of ITI Pharma and Healthcare Fund Direct Growth fund. The fund currently has an Asset Under Management(AUM) of ₹11,273 Cr and the Latest NAV as of 19 Jan 2026 is ₹16.55. The ITI Pharma and Healthcare Fund Direct Growth is rated Very High risk. Minimum SIP Investment is set to ₹500. Minimum Lumpsum Investment is ₹5,000. Exit load of 0.50%, if redeemed within 3 months. ;

Investment Objective

The scheme seeks to generate long term capital appreciation through investing in equity and equity related securities of companies engaged in Pharma and Healthcare.
Fund benchmarkNIFTY Healthcare Total Return Index.

Fund house

Rank (total assets)NA
Total AUM₹11,272.97 Cr
Date of Incorporation14 May 2018
Phone022-66214999
Launch Date14 May 2018
AddressITI Asset Mangement Limited,ITI House, Building no. 36,Dr. R. K. Shirodkar Marg, Parel, Mumbai 400012
CustodianDeutsche Bank
Registrar & Transfer AgentKFin Tech
AddressKarvy House, No. 46, 8-2-609/K, Avenue 4, Street No.1 Banjara Hills,